Crescent Biopharma dosed the first patient in its ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody for solid tumors. The company also reported Q1 2026 results and outlined pipeline milestones including ADC combination trials expected in the second half of 2026.
MacroGenics faces critical 2026 milestones for its ADC pipeline, including Phase 1 data for MGC026 and regulatory resolution for lorigerlimab. The company has financial runway through 2027 and plans IND submission for MGC030 in Q3 2026. Key investor events include ASCO abstract releases and financial results in Q2 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07745478 |
Effects of a Self-Regulation Based E-MOTE Program Delivered Via an AI-Assisted Robot and Supported by Mobile Platforms for Newly Diagnosed Gynecologic Cancer Patients |
NOT_YET_RECRUITING | NA |
| NCT01505400 |
Integrated Molecular Profiling in Advanced Cancers Trial |
ACTIVE_NOT_RECRUITING |
